Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

For the past decade, the standard treatment for patients with stage III non–small-cell lung cancer (NSCLC) has been concurrent chemoradiation. To explore the potential additive benefit of immunotherapy, investigators conducted an industry-funded, international, randomized, double-blind, phase III trial (PACIFIC), in which 713 patients with local-regionally advanced NSCLC received consolidation therapy with the PD-L1 inhibitor durvalumab or placebo for 1 year.

At median follow-up of 14.5 months, durvalumab recipients had superior median progression-free survival (PFS; 16.8 vs. 5.6 months; P<0.0001), a higher response rate (28.4% vs. 16.0%; P<0.001), prolonged duration of response at 18 months (72.8% vs. 46.8%), and longer median time to death…